Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue Recognition

Schedule of disaggregation of revenue

	Three Months Ended March 31,
	2024		2023
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	788	$	2,750
Total collaborative revenue	$	788	$	2,750
Commercial supply revenue
CSL Vifor* (KORSUVA injection)	$	640	$	3,191
Total commercial supply revenue	$	640	$	3,191
Royalty revenue
CSL Vifor (Kapruvia ex-U.S.)	$	—	$	125
Total royalty revenue	$	—	$	125
Clinical compound revenue
Maruishi	$	84	$	99
Total clinical compound revenue	$	84	$	99
Other revenue (non-cash)
CSL Vifor (Kapruvia ex-U.S.)	$	290	$	—
Maruishi		333		—
Total other revenue	$	623	$	—